<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608981</url>
  </required_header>
  <id_info>
    <org_study_id>CairoU_IL8</org_study_id>
    <nct_id>NCT04608981</nct_id>
  </id_info>
  <brief_title>Effect of Diclofenac Potassium Versus Prednisolone on Post-endodontic Pain and Pulpal IL-8 Expression</brief_title>
  <official_title>Effect of Diclofenac Potassium Versus Prednisolone as a Premedication on Post-endodontic Pain and Pulpal Interleukin (IL)-8 Expression in Symptomatic Irreversible Pulpitis Cases: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of using diclofenac potassium versus prednisolone as a pre-medication&#xD;
      compared to placebo on:&#xD;
&#xD;
        -  Intensity of post-endodontic pain in patients with symptomatic irreversible pulpitis.&#xD;
&#xD;
        -  Pulpal IL-8 expression.&#xD;
&#xD;
        -  Incidence of post-endodontic pain in patients with symptomatic irreversible pulpitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After confirming the diagnosis and making sure that the patient conforms to all eligibility&#xD;
      criteria, the principal investigator will enroll the patient in the study.&#xD;
&#xD;
        -  Patients will be asked to rate their pre-operative pain intensity (ie, before the&#xD;
           commencement of any treatment [baseline score]; on the visual analogue scale &quot;VAS&quot;&#xD;
&#xD;
        -  Enrolled patients will be randomly assigned into one of three groups:&#xD;
&#xD;
      Intervention Group 1 (Diclofenac Potassium): single, oral dose of 50 mg diclofenac potassium&#xD;
      pre-medication (Cataflam; NOVARTIS Pharma, Basel, Switzerland) one hour before starting&#xD;
      endodontic treatment.&#xD;
&#xD;
      Intervention Group 2 (Prednisolone): single, oral dose of 30 mg prednisolone (one and a half&#xD;
      tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France) 30 min before&#xD;
      starting endodontic treatment.&#xD;
&#xD;
      Control Group (Placebo): The patients assigned to this group will be given a placebo tablet&#xD;
      (Starch, Bridgewater, NJ) one hour before starting endodontic treatment.&#xD;
&#xD;
      - Root canal therapy in all groups will be completed by the principal investigator in a&#xD;
      single visit as follows:&#xD;
&#xD;
        1. Anesthetizing the tooth using inferior alveolar nerve block technique by local&#xD;
           anesthesia of 1.8 ml of 2% Mepivacaine HCl with 1:100,000 epinephrine.&#xD;
&#xD;
        2. After anesthesia is achieved and verified with Endo-Ice, the patient's tooth is isolated&#xD;
           with a rubber dam, caries is excavated, and the pulp is exposed with a sterile round&#xD;
           bur.&#xD;
&#xD;
        3. Preparation of access cavity using a sterile round carbide bur and an Endo-Z bur&#xD;
&#xD;
        4. Sample Collection:&#xD;
&#xD;
             -  Blood from the exposed surface of the pulp will be collected with 2 sterile cotton&#xD;
                pellets.&#xD;
&#xD;
             -  The pellets will be held at the exposure site for 45-60 seconds to allow absorption&#xD;
                of the blood from the pulpal tissue.&#xD;
&#xD;
             -  The pellets will be placed in 1.0 mL saline in heparin-coated tubes.&#xD;
&#xD;
             -  Samples will be placed on ice and stored/refrigerated immediately at -20 degrees&#xD;
                celsius until they are ready to be tested.&#xD;
&#xD;
        5. After the pulpal blood sample is collected, patency of the root canals will be confirmed&#xD;
           using stainless steel hand K-files sizes #10 and #15.&#xD;
&#xD;
        6. Working length will be determined using an electronic apex locator then confirmed&#xD;
           radiographically to be 1 mm shorter than radiographic apex.&#xD;
&#xD;
        7. Mechanical preparation will be completed in a crown down technique with ProTaper Next10&#xD;
           rotary files set on an endodontic motor adjusted at a speed of 300 rpm and torque of 200&#xD;
           gcm. In-and-out motions will be applied with stroke lengths not exceeding 3mm in the&#xD;
           cervical, middle, and apical thirds until attaining the established WL.&#xD;
&#xD;
        8. The root canal will be thoroughly irrigated with 3 mL of 2.6% sodium hypochlorite using&#xD;
           a plastic disposable syringe with a 30-gauge side-vented needle reaching 1mm short of&#xD;
           the working length between every subsequent instrument, whereas saline will be used as&#xD;
           the final irrigant.&#xD;
&#xD;
        9. The canal will then be dried using sterile paper points. Master cone fit radiograph will&#xD;
           be taken and then the root canal will be obturated at the same appointment with&#xD;
           matching-size gutta percha points and resin-based sealer using cold lateral compaction&#xD;
           technique.&#xD;
&#xD;
       10. Access cavity will be sealed with Coltosol F temporary filling material.&#xD;
&#xD;
       11. At the end of the session, each patient will be instructed to complete a pain diary,&#xD;
           (VAS), at specific intervals; immediately after treatment completion; and 6, 12, 24, and&#xD;
           48 hours after the completion of treatment. The patient will be asked to mark the level&#xD;
           of pain on this 10-cm line. The distance from the left end to the mark made by the&#xD;
           patient, which will be measured by the operator with a ruler, is the pain intensity.&#xD;
&#xD;
       12. Patients will be contacted by their operator at each time-point to check on them and as&#xD;
           a reminder. Then, information will be documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In this proposed study, the participant, and the assessor will be blinded. The participants will be blinded to the study hypothesis as to which intervention is expected to be better.&#xD;
The patients, who already do not know their treatment group, will assess the level of their post-endodontic pain.&#xD;
The laboratory technician at the microbiological department will not know the treatment group of the patients.&#xD;
The treatment groups will remain anonymous at the end of the study during assessment by the statistician.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the intensity of post-endodontic pain</measure>
    <time_frame>Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively</time_frame>
    <description>Pain intensity will be evaluated using visual analogue scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of pulpal IL-8</measure>
    <time_frame>During the procedure</time_frame>
    <description>Il-8 analasys will be done via enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the incidence of post-endodontic pain</measure>
    <time_frame>Immediately after treatment completion; and at 6, 12, 24, and 48 hours post-operatively</time_frame>
    <description>Pain incidence will be evaluated using visual analogue scale</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Symptomatic Irreversible Pulpitis</condition>
  <arm_group>
    <arm_group_label>Prednisolone premedication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, oral dose of 30 mg prednisolone pre-medication 30 min before starting endodontic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac potassium premedication</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, oral dose of 50 mg diclofenac potassium pre-medication 1 hour before starting endodontic treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet 1 hour before starting endodontic treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone 30 mg</intervention_name>
    <description>Steroidal anti-inflammatory drug as a preoperative medication</description>
    <arm_group_label>Prednisolone premedication</arm_group_label>
    <other_name>One and a half tablets Solupred oro 20 mg, ARE, Aventis Intercontinental, Paris, France</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Potassium 50mg Tab</intervention_name>
    <description>Non-steroidal anti-inflammatory drug as a preoperative medication</description>
    <arm_group_label>Diclofenac potassium premedication</arm_group_label>
    <other_name>Cataflam; NOVARTIS Pharma, Basel, Switzerland</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Starch</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18-50 years.&#xD;
&#xD;
          -  Males and females.&#xD;
&#xD;
          -  American Society of Anesthesiologists class 1 or 2.&#xD;
&#xD;
          -  Mandibular premolar teeth with:&#xD;
&#xD;
               -  Endodontic pulpal diagnosis of symptomatic irreversible pulpitis&#xD;
&#xD;
               -  Normal/slight widening in the periodontal membrane space (PMS).&#xD;
&#xD;
          -  Patients who had not taken any anti-inflammatory drugs the day of the root canal&#xD;
             procedure unless they belong to one of the intervention groups.&#xD;
&#xD;
          -  Patients who accept to participate in the trial, understand the VAS, and can sign the&#xD;
             informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cases with acute peri-apical conditions (acute apical periodontitis/ acute apical&#xD;
             abscess), pulpal necrosis, previously initiated therapy, or previously treated.&#xD;
&#xD;
          -  Teeth other than single-rooted teeth.&#xD;
&#xD;
          -  Radiographic evidence of external or internal root resorption vertical root fracture,&#xD;
             perforation, or calcification.&#xD;
&#xD;
          -  Immature teeth.&#xD;
&#xD;
          -  Unrestorable teeth or teeth with severe periodontal disease.&#xD;
&#xD;
          -  Patients with a known allergy, sensitivity, or history of other adverse reactions to&#xD;
             the medications administered.&#xD;
&#xD;
          -  Patients with a history of active peptic ulcer within the preceding 12 months,&#xD;
             bleeding problems, anticoagulant use within the last month, or kidney disease.&#xD;
&#xD;
          -  Patients who took analgesics/ anti-inflammatory drugs (steroidal or non-steroidal) the&#xD;
             day of endodontic treatment.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  Patients who are unable to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed A Soliman, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khaled Ezzat, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara S Abouelenien, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed A Soliman, MSc</last_name>
    <phone>+201006779533</phone>
    <email>aasoliman89@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sara S Abouelenien, PhD</last_name>
    <phone>+201000703203</phone>
  </overall_contact_backup>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 13, 2020</study_first_submitted>
  <study_first_submitted_qc>October 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2020</study_first_posted>
  <last_update_submitted>October 25, 2020</last_update_submitted>
  <last_update_submitted_qc>October 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Adel Abdullah Ali Soliman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prednisolone</keyword>
  <keyword>diclofenac potassium</keyword>
  <keyword>interleukin-8</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulpitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

